United Therapeutics‘ (UTHR) fourth-quarter 2023 earnings of $4.36 per share beat the Zacks Consensus Estimate of$3.92. Earnings rose 63% year over year on the back of higher product sales.Revenues in the reported quarter were $614.7 million, beating the Zacks Consensus Estimate of$562 million. Revenues rose 25% year over year, driven by Tyvaso sales.Quarter in DetailUnited Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Remodulin, Tyvaso, Adcirca and Orenitram. It also marke ...